Literature DB >> 21901382

Are we ready for an early evaluation of the response of axillary lymph node metastases to neoadjuvant therapy?

Laura Gilardi, Concetta De Cicco, Giovanni Paganelli.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21901382     DOI： 10.1007/s00259-011-1921-y

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN： 1619-7070            Impact factor:   9.236


× No keyword cloud information.
  7 in total

1.  Investigation of 18F-FDG PET in the selection of patients with breast cancer as candidates for sentinel node biopsy after neoadjuvant therapy.

Authors:  Laura Gilardi; Concetta De Cicco; Marco Colleoni; Anna Cardillo; Emilia Montagna; Silvia Dellapasqua; Viviana Galimberti; Vincenzo Bagnardi; Giovanni Paganelli
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-06-10       Impact factor: 9.236

2.  Suboptimal and inadequate quantification: an alarming crisis in medical applications of PET.

Authors:  Sandip Basu; Thomas C Kwee; Drew Torigian; Babak Saboury; Abass Alavi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-03-18       Impact factor: 9.236

3.  Early prediction of response to chemotherapy in metastatic breast cancer using sequential 18F-FDG PET.

Authors:  Joerg Dose Schwarz; Michael Bader; Lars Jenicke; Gabriele Hemminger; Fritz Jänicke; Norbert Avril
Journal:  J Nucl Med       Date:  2005-07       Impact factor: 10.057

4.  Disease-free and overall survival after pathologic complete disease remission of cytologically proven inflammatory breast carcinoma axillary lymph node metastases after primary systemic chemotherapy.

Authors:  Bryan T Hennessy; Ana Maria Gonzalez-Angulo; Gabriel N Hortobagyi; Massimo Cristofanilli; Shu Wan Kau; Kristine Broglio; Bruno Fornage; S Eva Singletary; Aysegul Sahin; Aman U Buzdar; Vicente Valero
Journal:  Cancer       Date:  2006-03-01       Impact factor: 6.860

5.  Incidence and prognostic significance of complete axillary downstaging after primary chemotherapy in breast cancer patients with T1 to T3 tumors and cytologically proven axillary metastatic lymph nodes.

Authors:  Roman Rouzier; Jean-Marc Extra; Jerzy Klijanienko; Marie-Christine Falcou; Bernard Asselain; Anne Vincent-Salomon; Philippe Vielh; Edwige Bourstyn
Journal:  J Clin Oncol       Date:  2002-03-01       Impact factor: 44.544

6.  FDG PET evaluation of early axillary lymph node response to neoadjuvant chemotherapy in stage II and III breast cancer patients.

Authors:  Caroline Rousseau; Anne Devillers; Mario Campone; Loïc Campion; Ludovic Ferrer; Christine Sagan; Myriam Ricaud; Boumédiène Bridji; Françoise Kraeber-Bodéré
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-02-10       Impact factor: 9.236

7.  The role of chemotherapeutic drugs in the evaluation of breast tumour response to chemotherapy using serial FDG-PET.

Authors:  Michal E Schneider-Kolsky; Stewart Hart; Jane Fox; Peter Midolo; John Stuckey; Michael Hofman; Vinod Ganju
Journal:  Breast Cancer Res       Date:  2010-06-21       Impact factor: 6.466
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.